| Eligibility |
Inclusion Criteria:
1. Willing and able to give voluntary written informed consent
2. Is able to read and write, able to communicate effectively with the investigator, and
comply with all study requirements, restrictions, and directions of the research staff
3. Men or women, aged 18 to 70, at screening
4. In good general health as evidenced by medical history, physical examination, ECG,
serum/urine biochemistry, hematology, and serology tests
5. Participants with PTSD will have a current diagnosis of PTSD according to DSM-5
criteria (CAPS-5 ascertained diagnosis, confirmed by the Principal Investigators. TC
subjects must have a DSM-5 criteria traumatic event with no PTSD diagnosis
6. Participants with AUD will have a current diagnosis of AUD according to DSM-5 criteria
(i.e., SCID-5 ascertained diagnosis, confirmed by the Principal Investigators);
7. Participants with AUD will meet the following drinking criteria: males will drink > 14
drinks per week and exceed 4 drinks per day at least twice per week; females will
drink > 7 drinks per week and exceed 3 drinks per day at least twice per week. They
must meet drinking criteria during a consecutive 30-day period within the 90 days
prior to intake.
8. Healthy subjects will have no current or past diagnosis of AUD or other significant
substance use disorder. They will drink less than 5 alcoholic drinks per week with no
heavy drinking days (i.e., >4 drinks/day for men; >3 drinks/day for women) in the last
30 days;
Exclusion Criteria:
1. Current significant medical condition such as neurological, cardiovascular, endocrine,
renal, liver, or thyroid pathology that would impact the integrity of the data (note
that elevated liver enzymes for individuals with AUD will not be exclusionary)
2. Past or current neurological disorder or disorders affecting the brain including but
not limited to multiple sclerosis, history of stroke, brain tumors, traumatic brain
injury with loss of consciousness, seizure disorder;
3. Current significant psychiatric disorder including severe substance use disorder
(other than alcohol or tobacco use disorders*), and past or current psychotic
symptoms,
4. Regular use in the past 6 months of any prescription, psychoactive or herbal
medications (e.g., antidepressants, antipsychotics, anxiolytics) that would impact the
integrity of the data (e.g., naltrexone); No subject will be asked to stop taking
medication to participate in the study;
5. Pregnancy or lactation
6. Blood donation within eight weeks of the start of the study.
7. History of a bleeding disorder or are currently taking anticoagulants (such as
Coumadin, Heparin, Pradaxa, Xarelto).
8. Unable to safely discontinue or hold aspirin and other NSAID use
9. MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable
body piercings) and other contraindications for MRI, such as claustrophobia, having
implanted or embedded metal objects/fragments or fragments in the head or body that
would present a risk during the MRI scanning procedure, or have worked with ferrous
metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or
machinist).
10. Participation in other research studies involving inonizing radiation within one year
of the PET scans that would cause the subject to exceed the yearly dose limits for
healthy volunteers.
11. Subject who has current, past, or anticipated exposure to radiation in the work place
within one year of the proposed research scans that in combination with the study
tracer would result in a cumulative exposure that exceeds recommended exposure limits.
12. Has any condition that, in the opinion of the investigator, would prevent compliance
with the study protocol.
13. History of complicated alcohol withdrawal including history of delirium tremens;
seizure, hospitalization for withdrawal.
14. Alcohol intoxication at time of screening.
15. A CIWA score =8 at intake or on scan day.
16. Subjects who are, in the opinion of the study physician, unable to safely abstain from
alcohol overnight prior to their study visits.
|
